This slide deck overviews results of key trials of monoclonal antibodies to CGRP and its receptor.
Therapeutic monoclonal antibodies directed against CGRP or the CGRP receptor show much promise in preventing migraine. To date, there are four monoclonal antibodies in development: ALD403, erenumab (AMG 334), galcanezumab (LY2951742) and TEV-48125. Efficacy and safety results from key clinical trials with each agent are discussed. These agents provide new hope for migraine patients for whom current options are either ineffective, poorly tolerated or restricted.
Download slideset »